Evidence map›Paper›PMID 16845437›Full record

ArticleNeuron glia biology2004

Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes.

Sharon Furman, Ruth A Steingart, Shmuel Mandel, Janet M Hauser, Douglas E Brenneman, Illana Gozes

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuron glia biology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01056965 (A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide), which is not on this map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01056965 phase1completednot on this mapstarted 2010, after this paper: background citation

A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies

TypeinterventionalSponsorUniversity of California, San FranciscoRan2010 to 2012Enrolled12ConditionsPredicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration SyndromeArmsdavunetide (AL-108, NAP), Placebo nasal spray
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 93 citations in OpenAlex.

  1. Article
  2. The chromatin remodeler ADNP regulates neurodevelopmental disorder risk genes and neocortical neurogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Moderate Physical Activity Increases the Expression of ADNP in Rat Brain.International journal of molecular sciences · 2024
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sharon FurmanDepartment of Clinical Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Einstein Street, Tel-Aviv 69978, Israel.
Ruth A Steingart
Shmuel Mandel
Janet M Hauser
Douglas E Brenneman
Illana Gozes
Tel Aviv University · ILNational Institutes of Health · US

Funding

NEUROPEPTIDES AND CELLULAR INTERACTIONSF15TW000370 · FIC · U.S. NATIONAL INSTITUTE OF MENTAL HEALTH · PI GOZES, ILLANA · 1995 to 1996
–
FIC NIH HHS F15 TW000370
6 · The paper itself

Abstract

Activity-dependent neuroprotective protein (ADNP, approximately 123562.8 Da), is synthesized in astrocytes and expression of ADNP mRNA is regulated by the neuroprotective peptide vasoactive intestinal peptide (VIP). The gene that encodes ADNP is conserved in human, rat and mouse, and contains a homeobox domain profile that includes a nuclear-export signal and a nuclear-localization signal. ADNP is essential for embryonic brain development, and NAP, an eight-amino acid peptide that is derived from ADNP, confers potent neuroprotection. Here, we investigate the subcellular localization of ADNP through cell fractionation, gel electrophoresis, immunoblotting and immunocytochemistry using alpha-CNAP, an antibody directed to the neuroprotective NAP fragment that constitutes part of an N-terminal epitope of ADNP. Recombinant ADNP was used as a competitive ligand to measure antibody specificity. ADNP-like immunoreactivity was found in the nuclear cell fraction of astrocytes and in the cytoplasm. In the cytoplasm, ADNP-like immunoreactivity colocalized with tubulin-like immunoreactivity and with microtubular structures, but not with actin microfilaments. Because microtubules are key components of developing neurons and brain, possible interaction between tubulin and ADNP might indicate a functional correlate to the role of ADNP in the brain. In addition, ADNP-like immunoreactivity in the extracellular milieu of astrocytes increased by approximately 1.4 fold after incubation of the astrocytes with VIP. VIP is known to cause astrocytes to secrete neuroprotective/neurotrophic factors, and we suggest that ADNP constitutes part of this VIP-stimulated protective milieu.

Identifiers

PMID16845437
PMCPMC1502393
OpenAlexW2016772796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.